Explain this page
Arphra AIPlain-English read on Guardant Health, Inc.’s valuation06-04today
- Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®4d
- Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®4d
- Here's Why This Colon Cancer Testing Biotech Is A Mutual Fund Favorite11d
- Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript34d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$23.58
-81.83% vs spot
Recommendation
Sell
3 of 4 methods
Method spread
0bull3bear
±5% threshold
Analyst PT consensus: $147.00 (+13.23%)
Candlestick · 1Y
Open in chart workstation →GH
131.62+14.55%H 133.97L 74.55MA50 100.72MA200 —Avg vol 2.2M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.37% | -0.14% | +36.77% | +51.85% | +26.44% | +27.10% | +163.33% | +242.89% | +10.31% | +303.17% | +303.17% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$1.23M
1 txn
Net flow
−$1.23M
Aftermarket
LiveLast trade
$129.82
92 sh
Bid
$128.65
3 sh
Ask
$134.00
19 sh
Spread
$5.350
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $281.27M | -$128.49M | $-1.00 |
| Q3 Sep 2025 | $265.2M | -$92.73M | $-0.74 |
| Q2 Jun 2025 | $232.09M | -$99.9M | $-0.80 |
| Q1 Mar 2025 | $203.47M | -$95.16M | $-0.77 |
| Q4 Dec 2024 | $201.81M | -$111.01M | $-0.90 |
| Q3 Sep 2024 | $191.48M | -$107.75M | $-0.88 |
Sector & industry today
LiveSectors
- Financial Services+1.25%
- Utilities+0.89%
- Communication Services+0.47%
- Energy+0.45%
- Technology+0.29%
- Consumer Defensive-0.19%
- Industrials-0.30%
- Healthcare-0.38%
- Real Estate-0.66%
- Consumer Cyclical-0.94%
- Basic Materials-1.05%
Top industries (issuer's industry highlighted)
- Medical - Diagnostics & Research-0.00%
- Department Stores-4.91%
- Broadcasting-4.11%
- Oil & Gas Energy+3.74%
- Trucking-3.73%
- Education & Training Services-3.10%
- Electronic Gaming & Multimedia+2.81%
- Coal-2.80%
- Steel-2.67%
- Copper-2.60%
- Regulated Water+2.54%
- Medical - Equipment & Services+2.46%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®businesswire.com·Jun 11, 2026
- Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®businesswire.com·Jun 11, 2026
- Here's Why This Colon Cancer Testing Biotech Is A Mutual Fund Favoriteinvestors.com·Jun 04, 2026
- Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 12, 2026
- Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcriptseekingalpha.com·May 08, 2026
- Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metricszacks.com·May 07, 2026
- Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimateszacks.com·May 07, 2026
- Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidancebusinesswire.com·May 07, 2026
Recent analyst activity
DB- Jun 11, 2026PT$185.00RBC Capital Starts Guardant Health (GH) at Outperform, 'Underpenetrated Market'RBC Capital
- Jun 11, 2026GradeOutperformRBC Capital Starts Guardant Health (GH) at Outperform, 'Underpenetrated Market'RBC Capital
- Jun 08, 2026PT$175.00Guardant Health price target raised to $175 from $135 at MizuhoMizuho Securities
- Jun 05, 2026PT$165.00Goldman Sachs Starts Guardant Health (GH) at BuyGoldman Sachs
- Jun 05, 2026GradeNeutral → BuyGoldman Sachs Starts Guardant Health (GH) at BuyGoldman Sachs
- Jun 02, 2026GradeOutperformGuardant Health upgraded to Outperform from In Line at Evercore ISIEvercore ISI
- Jun 02, 2026PT$160.00Guardant Health upgraded to Outperform from In Line at Evercore ISIEvercore ISI
Peers
No peer list available for GH.
Total assets
$2.01B
Total debt
$1.68B
Cash & equiv
$378.2M
Operating CF
-$184.76M
Free cash flow
-$233.07M
Buybacks
$13.59M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Krognes Steve E. director | Sell | 9,294 | $1.23M | Jun 04, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $982.02M | -$436.3M | -$416.28M | $-3.32 | -42.39% |
| FY 2024 | $739.02M | -$443.59M | -$436.37M | $-3.56 | -59.05% |
| FY 2023 | $563.95M | -$564.73M | -$479.45M | $-4.28 | -85.02% |
| FY 2022 | $449.54M | -$544.38M | -$654.59M | $-6.41 | -145.61% |
| FY 2021 | $373.65M | -$411M | -$405.67M | $-3.80 | -108.57% |